Literature DB >> 18524763

BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner.

Stella Maris Ranuncolo1, Ling Wang, Jose M Polo, Tania Dell'Oso, Jamil Dierov, Terry J Gaymes, Feyruz Rassool, Martin Carroll, Ari Melnick.   

Abstract

The BCL6 oncogenic transcriptional repressor is required for development of germinal center centroblasts, which undergo simultaneous genetic recombination and massive clonal expansion. Although BCL6 is required for survival of centroblasts, its expression in earlier B-cells is toxic. Understanding these opposing effects could provide critical insight into normal B-cell biology and lymphomagenesis. We examined the transcriptional and biological effects of BCL6 in various primary cells. BCL6 repression of ATR was previously shown to play a critical role in the centroblast phenotype. Likewise, we found that BCL6 could impose an ATR-dependent phenotype of attenuated DNA damage sensing and repair in primary fibroblasts and B-cells. BCL6 induced true genomic instability because DNA repair was delayed and was qualitatively impaired, which could be critical for BCL6-induced lymphomagenesis. Although BCL6 can directly repress TP53 in centroblasts, BCL6 induced TP53 expression in primary fibroblasts and B-cells, and these cells underwent p53-dependent growth arrest and senescence in the presence of physiological levels of BCL6. This differential ability to trigger a functional p53 response explains at least in part the different biological response to BCL6 expression in centroblasts versus other cells. The data suggest that targeted re-activation of TP53 could be of therapeutic value in centroblast-derived lymphomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524763      PMCID: PMC2504889          DOI: 10.1074/jbc.M803490200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  BCL-6 in the pathogenesis of non-Hodgkin's lymphoma.

Authors:  B H Ye
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

2.  A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.

Authors:  Avi Shvarts; Thijn R Brummelkamp; Ferenc Scheeren; Eugene Koh; George Q Daley; Hergen Spits; René Bernards
Journal:  Genes Dev       Date:  2002-03-15       Impact factor: 11.361

3.  Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter.

Authors:  K Boggs; D Reisman
Journal:  Oncogene       Date:  2006-01-26       Impact factor: 9.867

4.  AID is required for germinal center-derived lymphomagenesis.

Authors:  Laura Pasqualucci; Govind Bhagat; Mila Jankovic; Mara Compagno; Paula Smith; Masamichi Muramatsu; Tasuku Honjo; Herbert C Morse; Michel C Nussenzweig; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

5.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

6.  Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

Authors:  Stella Maris Ranuncolo; Jose M Polo; Jamil Dierov; Michael Singer; Tracy Kuo; John Greally; Roland Green; Martin Carroll; Ari Melnick
Journal:  Nat Immunol       Date:  2007-06-10       Impact factor: 25.606

7.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.

Authors:  L Pasqualucci; P Neumeister; T Goossens; G Nanjangud; R S Chaganti; R Küppers; R Dalla-Favera
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

8.  A new functional domain of Bcl6 family that recruits histone deacetylases.

Authors:  H Zhang; S Okada; M Hatano; S Okabe; T Tokuhisa
Journal:  Biochim Biophys Acta       Date:  2001-09-26

9.  The human BCL6 transgene promotes the development of lymphomas in the mouse.

Authors:  Beverly W Baron; John Anastasi; Anthony Montag; Dezheng Huo; Rebecca M Baron; Theodore Karrison; Michael J Thirman; Sumit K Subudhi; Robert K Chin; Dean W Felsher; Yang-Xin Fu; Timothy W McKeithan; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-16       Impact factor: 11.205

10.  BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

Authors:  Samir Parekh; Jose M Polo; Rita Shaknovich; Przemyslaw Juszczynski; Paola Lev; Stella M Ranuncolo; Yingnan Yin; Ulf Klein; Giorgio Cattoretti; Riccardo Dalla Favera; Margaret A Shipp; Ari Melnick
Journal:  Blood       Date:  2007-06-01       Impact factor: 22.113

View more
  19 in total

Review 1.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

2.  A kinase shRNA screen links LATS2 and the pRB tumor suppressor.

Authors:  Katrin Tschöp; Andrew R Conery; Larisa Litovchick; James A Decaprio; Jeffrey Settleman; Ed Harlow; Nicholas Dyson
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

3.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Authors:  Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2009-03-23       Impact factor: 22.113

4.  Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression.

Authors:  Min-Kyeong Kim; Ji-Yang Song; Dong-In Koh; Jin Young Kim; Masahiko Hatano; Bu-Nam Jeon; Min-Young Kim; Su-Yeon Cho; Kyung-Sup Kim; Man-Wook Hur
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

5.  LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas.

Authors:  Cristina Bertolo; Sergio Roa; Ainara Sagardoy; Maria Mena-Varas; Eloy F Robles; Jose I Martinez-Ferrandis; Xavier Sagaert; Thomas Tousseyn; Alberto Orta; Izidore S Lossos; Salomon Amar; Yasodha Natkunam; Javier Briones; Ari Melnick; Raquel Malumbres; Jose A Martinez-Climent
Journal:  Br J Haematol       Date:  2013-06-25       Impact factor: 6.998

6.  The BTB-ZF family of transcription factors: key regulators of lineage commitment and effector function development in the immune system.

Authors:  Aimee M Beaulieu; Derek B Sant'Angelo
Journal:  J Immunol       Date:  2011-09-15       Impact factor: 5.422

7.  TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.

Authors:  Leandro Venturutti; Matt Teater; Andrew Zhai; Amy Chadburn; Leena Babiker; Daleum Kim; Wendy Béguelin; Tak C Lee; Youngjun Kim; Christopher R Chin; William T Yewdell; Brian Raught; Jude M Phillip; Yanwen Jiang; Louis M Staudt; Michael R Green; Jayanta Chaudhuri; Olivier Elemento; Pedro Farinha; Andrew P Weng; Michael D Nissen; Christian Steidl; Ryan D Morin; David W Scott; Gilbert G Privé; Ari M Melnick
Journal:  Cell       Date:  2020-07-02       Impact factor: 41.582

Review 8.  Pathogenesis of human B cell lymphomas.

Authors:  Arthur L Shaffer; Ryan M Young; Louis M Staudt
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

9.  BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells.

Authors:  Saritha Kusam; Veerendra Munugalavadla; Deepali Sawant; Alexander Dent
Journal:  Int J Cancer       Date:  2009-08-15       Impact factor: 7.396

10.  Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

Authors:  Huimin Geng; Sarah Brennan; Thomas A Milne; Wei-Yi Chen; Yushan Li; Christian Hurtz; Soo-Mi Kweon; Lynette Zickl; Seyedmehdi Shojaee; Donna Neuberg; Chuanxin Huang; Debabrata Biswas; Yuan Xin; Janis Racevskis; Rhett P Ketterling; Selina M Luger; Hillard Lazarus; Martin S Tallman; Jacob M Rowe; Mark R Litzow; Monica L Guzman; C David Allis; Robert G Roeder; Markus Müschen; Elisabeth Paietta; Olivier Elemento; Ari M Melnick
Journal:  Cancer Discov       Date:  2012-10-29       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.